BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12397697)

  • 1. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
    Shibasaki Y; Nishiue T; Masaki H; Matsubara H; Iwasaka T
    Nihon Rinsho; 2002 Oct; 60(10):1992-8. PubMed ID: 12397697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
    Shibasaki Y; Masaki H; Nishiue T; Nishikawa M; Matsubara H; Iwasaka T
    Nephron; 2002 Mar; 90(3):256-61. PubMed ID: 11867945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers.
    Shibasaki Y; Nishiue T; Masaki H; Tamura K; Matsumoto N; Mori Y; Nishikawa M; Matsubara H; Iwasaka T
    Hypertens Res; 2005 Oct; 28(10):787-95. PubMed ID: 16471172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan.
    Avanza AC; El Aouar LM; Mill JG
    Arq Bras Cardiol; 2000 Feb; 74(2):103-17. PubMed ID: 10904284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
    Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G
    Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
    Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan.
    Yu G; Liang X; Xie X; Yang T; Sun M; Zhao S
    Chin Med J (Engl); 2002 Sep; 115(9):1287-91. PubMed ID: 12411096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.
    Ligtenberg G; Blankestijn PJ; Oey PL; Klein IH; Dijkhorst-Oei LT; Boomsma F; Wieneke GH; van Huffelen AC; Koomans HA
    N Engl J Med; 1999 Apr; 340(17):1321-8. PubMed ID: 10219067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
    Xu R; Zhang Y; Zhang M; Li XC; Cai H; Chen WQ; Zhu H; Ge ZM; Zhang W
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3199-204. PubMed ID: 16405840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M; Tylicki L; Rutkowski P; Rutkowski B
    Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats.
    Kim S; Ohta K; Hamaguchi A; Yukimura T; Miura K; Iwao H
    Br J Pharmacol; 1996 Jun; 118(3):549-56. PubMed ID: 8762077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
    Vizir VA; Berezin AE
    Ter Arkh; 2002; 74(1):52-5. PubMed ID: 11878061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients.
    Wu SC; Liu CP; Chiang HT; Lin SL
    Heart Vessels; 2004 Jan; 19(1):13-8. PubMed ID: 14685749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
    Schieffer B; Wirger A; Meybrunn M; Seitz S; Holtz J; Riede UN; Drexler H
    Circulation; 1994 May; 89(5):2273-82. PubMed ID: 8181153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension.
    Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Murakami K; Higaki J
    Clin Ther; 2006 Oct; 28(10):1677-85. PubMed ID: 17157123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.